President and Founder
Janet Wolfe, Ph.D. is President and Founder of Wolfe Laboratories, Inc. Dr. Wolfe is a biopharma thought leader and has built and led development programs for small molecules and biologics across multiple therapeutic areas such as CNS, cardiovascular, metabolic diseases, immunology and oncology. Dr. Wolfe has contributed to the advancement of molecules through all stages of development and commercialization. Prior to starting Wolfe Laboratories in 1999, Dr. Wolfe was a faculty member with the Department of Pharmaceutical Sciences at the University of Tennessee, following her postdoctoral fellowship at the National Institutes of Health. Dr. Wolfe authored numerous articles and presentations, and she is the recipient of numerous awards including being named as one of New England’s Top Entrepreneurs and Innovators by the Federal Reserve Bank of Boston and one of PharmaVoice’s 100 Most Inspiring Entrepreneurs in the Life Sciences. She was awarded the Leadership Prize from Women Entrepreneurs in Science and Technology and she was named Entrepreneur to Watch by MIT Enterprise Forum. Dr. Wolfe was also recognized as Boston’s Entrepreneur of the Year by the Greater Boston Chamber of Commerce. Dr. Wolfe holds a B.S. from the University of Sciences in Philadelphia and Ph.D. in Pharmaceutical Chemistry from the University of Kansas.
Senior Vice President and General Counsel
Paul Oakley is Senior Vice President and General Counsel at Wolfe Laboratories, Inc. Mr. Oakley is well-known for his business, legal and strategic perspective and is well-suited to lead and optimize Wolfe Laboratories’ growing business and operational strategies. Mr. Oakley has used his extensive cross-functional skill-set to build value and solve problems as a key contributor to nearly a dozen start-ups and high-growth, mission-oriented private companies, including advising management teams and corporate boards on a wide variety of matters and industries including software, telecommunications, information technology, life sciences, medical devices, energy and clean tech. In 2011, he was a co-founder of TrueLight Energy, an innovative firm engaged in short-term trading in the wholesale electricity markets. Previously, Mr. Oakley was outside general counsel for a portfolio of emerging growth companies while a corporate finance and transactional partner at Sullivan & Worcester, one of the leading private law firms headquartered in Boston. During his 16-year law firm career, he managed project teams in more than 40 M&A transactions, and closed more than 100 VC investment deals. Mr. Oakley holds a B.A. in English and Journalism from the University of Missouri-Columbia an M.A. in International Politics from Syracuse University and a J.D. from Syracuse University.
Vice President of Pharmaceutical Development
Frank Tagliaferri, Ph.D. is Vice President of Pharmaceutical Development at Wolfe Laboratories, Inc. Dr. Tagliaferri is a veteran pharmaceutical development executive with extensive experience in advancing complex therapeutics from the preclinical stage to commercialization. Previously, Dr. Tagliaferri co-founded and served as Vice President of R&D at 4P Therapeutics, where he focused on the design, characterization, and commercial development of novel delivery systems and drug/device combination products for biologics and other complex molecules. Prior to 4P Therapeutics, Dr. Tagliaferri served as Vice President of R&D for Altea Therapeutics where he contributed to the development of the PassPort® System for the transdermal delivery of small molecules and biologics. Dr. Tagliaferri served as Director of Drug Delivery and Preclinical R &D at Tapestry Pharmaceuticals, where he managed a research team developing small molecule anti-cancer agents and novel RNA-based therapeutics. He launched his career at GeneMedicine (later Valentis, Inc.), where, as Director of Drug Delivery, his focus was on the development and characterization of delivery systems for both DNA and proteins. Dr. Tagliaferri holds a B.S. from Franklin & Marshall College and a Ph.D. in Chemistry from University of Virginia.
Sheila DeWitt, Ph.D. serves on Wolfe Laboratories’ Board of Advisors. Dr. DeWitt is a life sciences executive and serial entrepreneur with thirty years of experience in biopharmaceutical companies, having founded/co-founded five companies (Diversomer, Orchid, Deuteria Pharmaceuticals, JSD Partners, DeuteRx). She is currently the President and CEO of DeuteRx. Previously, Dr. DeWitt was the President and CEO of Deuteria Pharmaceuticals, the parent company of DeuteRx. Prior to Deuteria, Dr. DeWitt was Vice President of Business Development, Discovery and Manufacturing at EPIX, where she led the $125M merger to transition the company from imaging to therapeutics (EPIX-Predix), led the $28M sale of the 1st FDA approved MRA imaging drug (EPIX-Lantheus), and managed global R&D functions through Phase 2 trials. In addition to numerous publications, patents and presentations, Dr. DeWitt is internationally recognized as a scientific pioneer in combinatorial chemistry (Parke-Davis, Diversomer), and she was recognized by Mass High Tech in its “Women to Watch” list in 2013. She serves on the Industry Advisory Council of ALD Connect, on the Board of Advisors of Gordon-Conwell Theological Seminary and the Biotechnology Advisory Board of Greater Lawrence Technical School. Dr. DeWitt holds her B.A. from Cornell University and Ph.D. in Synthetic Organic Chemistry from Duke University.
Michael Webb serves on Wolfe Laboratories’ Board of Advisors. Mr. Webb is President and CEO of Tyrogenex and its sister company, Xcovery. He has more than 25 years’ experience in growing biotechnology companies and a track record that includes raising more than $350 million in private and public equity markets. Previously, he was president and CEO of Allegro Diagnostic Corp., a venture-backed, molecular diagnostics company focused on lung cancer that was acquired by Veracyte in 2014. Prior Allegro, he founded and served as President and CEO for Anchor Therapeutics, Inc. During his time as President and CEO of EPIX Pharmaceuticals, he led the company from a Series A-round financing to an industry leader position in pharmaceuticals for diagnostic imaging and listing on NASDAQ. Mr. Webb has served as Chair of the Massachusetts Biotechnology Council, founding chairman of the United Way of Massachusetts Bay’s Math, Science and Technology Initiative and is a member of several boards. Mr. Webb holds an MBA from Northwestern University, a Master’s in International Relations from Sussex University and a B.A./B.S. in Biochemistry and Economics from the University of Kansas.